COMPANIES, START UP & SPIN-OFF
Vetogene is a services company which research activities are focused on the genetic control aimed to preserve health and welfare of domestic animals. DNA analysis for parentage and genetic diseases control are supplied, specialized veterinary medical consulting is available for behavioral problem in dogs and cats. Supplied services are characterized by high technologic content oriented to supply high quality tools in animal health and welfare protection.
Neuro-Zone s.r.l. mission is to support drug discovery programs by providing well controlled physiologically relevant primary cell models and a multiparametric cell-based assay platform in order to increase efficiency of lead optimization projects.
By combining over 15 years of basic research expertise in culturing physiologically relevant cell systems with innovative approaches in the fields of microengineering, microfluidics and advanced biocompatible materials, Neuro-Zone srl aims at becoming the reference company for both customized assistance to primary cell culturing activities and high profile lead optimization screening services.
Neuro-Zone s.r.l is the 2008 Winner of the Most Innovative and Creative Company in the Province of Milano and was ranked among the top 25 Most Innovative European Life Science SMEs at the 2009 Eurecan Venture Summit.
Kos Genetic provides a wide range of solutions, from basic research to high throughput genomic analyses of predictive and causative variants in complex diseases, and prototypal diagnostic tools for clinical practice. The working team is a group of expert researchers in biotechnologies, genetic epidemiology and animal genetic, supported by cutting-edge technology.
Kos Genetic's target markets are biotechnology and pharma companies, healthcare and academic/research centers, breeders consortiums and food manufacturers, to which the company offers its expertise in: genetic/genomic and post genomic analyses and services on complex human diseases, pharmacogenomic services for new drugs development, livestock genomic selection and database services to store, manage and query phenotypic and genotypic information for all animal and vegetable species.
Newlisi S.p.A. holds a unique patented technology named CSR (Chemical Sludge Reduction).His mission is to become the reference company in the excess sludge treatment, addressing what is currently one of the major concern of the wastewater treatment industry. Appling the CSR technology wastewater companies and consortia can highly improve their ecological footprint and reduce the disposing rising costs.
Newlisi's technology is the result of more than 8 years of research and field testing. The achieved results today allowed the construction of the first industrial test plant, actually in operation by one major Italian multi utility.
Newlisi has “360° Capital Partners”, one of the reference Venture Capital fund in Italy, as key partners and investor.
WISE s.r.l. (Wiringless Implantable Stretchable Electronics) is a start-up company with the mission of fabricating and commercially exploiting electronic and MEMS devices on stretchable supports for application in the fields of biotechnology, biomedicine and sensors. The activity of WISE is focused on the exploitation of a proprietary technology, namely the Supersonic Cluster Beam Implantation (SCBI), for the metallization of polymers and elastomers. SCBI allows fabricating complex microelectronic circuits and interconnects on stretchable and conformable supports preserving the electrical performances of the devices after extensive cycles of stretching and bending of the substrates. The devices can be efficiently fabricated on biocompatible platforms, and therefore are suitable for the production of implantable biomedical devices, as for instance electrodes for neurostimulation.
The Agency for Research on Amyotrophic Lateral Sclerosis (ALS) – Established on november 2008, AriSLA it is now the first example of cooperation between scientific research centers and philanthropic associations, both in Italy and across Europe. The goal of AriSLA founding members – Fondazione Cariplo, Fondazione Telethon, Fondazione Vialli e Mauro per la Ricerca e lo Sport and AISLA (Italian Association on Amyotrophic Lateral Sclerosis) - is to make research investments on ALS more effective and to support translational research to foster a quick transfer of research outcomes into the clinical practice. The Agency promote and support those researches that could have a tangible effect on both patients affected by ALS and their families. In addition, AriSLA will promote the setting up of a wide network of Italian and foreign researchers and scientific staff, to pull together the best resources in the field of ALS.
AISLA (Italian Association of Amyotrophic Lateral Sclerosis) is a non-profit organisation founded in 1983 and recognised by the Decree of 30 June 1999 by the Ministry of Health as the national certified point of reference for people suffering from ALS. Today the association has 57 local branches all over the country. AlS is an incurable neurodegenerative disease which leads to motor neuron premature death, causing a progressive weakening of voluntary muscles and lastly the patient's paralysis. AISLA aims to promote and finance scientific research and scolarships, to provide assistance and care to patients and their families, to organise training courses for care givers, medical and professional staff, to sensitize public awareness about ALS , also informing about new scientific perspectives/ scientific newnesses.
FONDAZIONE SERENA ONLUS
Fondazione Serena Onlus is a non-profit organization born form the collaboration among UILDM (Unione Italiana Lotta alla Distrofia Muscolare), Fondazione Telethon, AISLA (Associazione Italiana Sclerosi Laterale Amiotrofica), Azienda Ospedaliera Niguarda and Associazione Famiglie SMA Onlus. The 22nd of December, 2008, Fondazione Serena acquires the title of ONLUS (charity). CENTRO CLINICO NEMO is a Fondazione Serena ONLUS project Three years serving neuromuscular patients NEMO is the acronym of “NEuroMuscular Omnicentre. It's a Fondazione Serena ONLUS project , a non-profit association, founded by three voluntary organizations (UILDM, AISLA and Associazione Famiglie SMA), Telethon Foundation and Azienda Ospedaliera Niguarda. NEMO is considered a medical division leader for two specific features:
- it takes care of patients affected by neuromuscular pathologies, such as Muscular Dystrophy, ALS - Amyotrophic Lateral Sclerosis - and SMA - Spinal Muscular Atrophy;
- it includes, within its structure, all the peculiar clinical branches related to this kind of pathologies; from the neurologist to the physiatrist, to the lung specialist. The patient is placed at the center of the whole care process, with the sole aim of giving as much care as possible to him/her and his/her family. This purpose has real and positive impact on life quality.
Famiglie SMA is an association of parents of children affected by SMA; it has been founded in 2001 and currently has about 800 members nation-wide. Over the years it has become a main reference in Italy for all those involved, personally or professionally, in SMA. Family SMA has raised over 1.000.000 euros for:
- financing research;
- providing information support to the families;
- enhancing rehabilitation and care.